{"id":380718,"date":"2020-11-13T07:33:30","date_gmt":"2020-11-13T12:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380718"},"modified":"2020-11-13T07:33:30","modified_gmt":"2020-11-13T12:33:30","slug":"moleculin-biotech-inc-reports-financial-results-for-the-quarter-ended-september-30-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-biotech-inc-reports-financial-results-for-the-quarter-ended-september-30-2020\/","title":{"rendered":"Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n HOUSTON<\/span>, Nov. 13, 2020<\/span> \/PRNewswire\/ —\u00a0Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended September 30, 2020<\/span> and provided a business update.<\/p>\n

\n

\n
\n \"Moleculin
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Management Discussion<\/b>\n <\/p>\n

“We are extremely encouraged by the progress we made in the third quarter. Despite the sustained headwinds from the COVID-19 pandemic, we were able to drive the development of Annamycin both in our AML and lung indications, further progress our clinical trials for WP1066, expand and accelerate our infectious disease platform, and bolster our experienced leadership team,” commented Walter Klemp<\/span>, Chairman and CEO of Moleculin.<\/p>\n

“We were particularly encouraged by the progress we made advancing our lead candidate Annamycin, a ‘next generation anthracycline’ demonstrating little to no cardiotoxicity. In June, we conducted our End of Phase 1 meeting with the US Food and Drug Administration (“FDA”). As a result of this meeting, we will expand our protocol-mandated testing for cardiotoxicity throughout the remainder of the Phase 1 trial. This will provide additional safety data, including investigating the continued evidence of little to no cardiotoxicity, and efficacy data which both US and European regulators may consider as we prepare to transition to a Phase 2 clinical trial. We also received approval from Polish authorities to increase the dose-escalation from 30 mg\/m2 per cohort to 60 mg\/m2 per cohort which will accelerate finding the maximum tolerated dose.”<\/p>\n

“We were also excited by the promise Annamycin shows in targeting lung localized tumors. Currently there is an extreme unmet need for a more effective treatment of sarcomas that have metastasized to the lungs, and limited treatment options available for lung metastases resulting from a primary tumor, even though the primary tumor may have been treatable. In September, we were pleased to announce results from an independent laboratory demonstrating in animal studies the ability of Annamycin to generate a 30-fold greater concentration in lungs compared to the current standard of care drug, enabling the targeting of this cancer in its sanctuary site. These results further validate data we presented at the American Association of Cancer Research, which illustrated Annamycin’s uniquely high uptake and retention in the lungs, resulting in consistently high in vivo activity against a wide range of lung-localized tumors in mice. Due to Annamycin’s strong pre-clinical data in this indication, we successfully completed a pre-IND (Investigational New Drug) meeting with the FDA and discussed our development plan for Annamycin, including the clinical study design and dosing strategy for an initial Phase 1b<\/span>\/2 protocol for soft tissue sarcomas with lung metastases. Based on our conversations, and the compelling pre-clinical data, we are optimistic that we will be able to file an IND with the FDA for this indication before the end of the year.”<\/p>\n

“In addition to driving the development of Annamycin, we continued to advance WP1066, the lead molecule in Moleculin’s portfolio of immune stimulators and modulators of transcription. Importantly, we were able to report positive data from both our adult and pediatric Phase 1 clinical trials. In our adult Phase 1 clinical trial being conducted at a major cancer center in Houston<\/span>, we reported positive preliminary data in adult patients with glioblastoma (“GBM”), which supports the progression of the trial to the fourth and final dose escalation cohort. In our Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children being at conducted at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta<\/span>, the first three patients in the trial received treatment at a dose level of 4 mg\/kg with no adverse events related to WP1066 and the study is now proceeding to the next higher dose of 6 mg\/kg. Importantly, one patient with diffuse intrinsic pontine glioma (“DIPG”), showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size. We believe this to be particularly notable given the clinical trial history of DIPG, as approximately 200 clinical trials have been conducted with no drug showing significant activity in this disease.”<\/p>\n

“Although we remain laser focused on advancing our clinical pipeline, we are very encouraged by the potential our infectious disease pipeline continues to offer. Our initial preclinical focus for the WP1122 program was to help provide a treatment for the growing COVID-19 pandemic. Following strong preclinical data and independent research demonstrating WP1122’s unique mechanism of action and in-vitro activity, we were pleased to further progress our studies as we prepare for submission of an IND to test WP1122 in COVID-19 patients. During the quarter, we also discovered that two other molecules within our portfolio of antimetabolites displayed significant in vitro antiviral activity against SARS-CoV-2 and other hard to treat viruses. Independent laboratory testing of our new drug candidates, called WP1096 and WP1097, not only showed significant antiviral activity against SARS-CoV-2, but also showed greater potential against HIV, Zika, and Dengue Fever. While we are encouraged by the strong preclinical data, we believe our best course of action for advancing this portfolio given its early stage will be through relying on collaborations and externally funded pathways. Subsequently, we entered into an agreement with the University of Campinas in S\u00e3o Paulo, Brazil<\/span> to further enable collaboration into research on the anti-viral capabilities of WP1122, specifically for the coronavirus. We continue to be optimistic about the data demonstrated in the WP1122 portfolio and are planning to file an IND application or its equivalent for either cancer-related or virus-related clinical trials in the first half of 2021.”<\/p>\n

Mr. Klemp concluded, “As we head into the final months of 2020, we believe we remain well-positioned to progress our three core technologies. To help drive this effort, we recently appointed Liz Cermak<\/span> to our Board of Directors. Liz brings nearly four decades of healthcare experience, has helped oversee drugs through commercialization, and has licensed drugs to well respected big pharmaceutical companies. With our experienced leadership team, and the progress we made throughout the third quarter, we look forward to building on our momentum, and executing on our strategic plan as we head into 2021.”<\/p>\n

\n Recent Milestones and Accomplishments:<\/b>\n <\/p>\n

\n Next Generation Anthracycline – Annamycin<\/b>\n <\/p>\n